12:00 AM
Aug 12, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Imnovid pomalidomide regulatory update

The European Commission approved Imnovid pomalidomide from Celgene to treat patients with relapsed and refractory multiple myeloma (MM). Imnovid is approved in combination with dexamethasone in adults who have received >=2 prior therapies, including both Velcade bortezomib and Celgene's Revlimid lenalidomide, and whose disease progressed while on...

Read the full 231 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >